CSTL Q3 2019 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CSTLCastle Biosciences, Inc.

$772M

Q3 2019 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$15M+298.1% YoY

Gross Profit

$13M88.4% margin

Operating Income

$4M30.0% margin

Net Income

$6M39.6% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

+37.6%

Cash Flow

Operating Cash Flow

$751,542

Free Cash Flow

$586,351

Stock-Based Comp.

$229,484

Balance Sheet

Total Assets

$113M

Total Liabilities

$31M

Stockholders' Equity

$82M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$4M	+298.1%
Gross Profit	$13M	$2M	+453.4%
Operating Income	$4M	-$3M	+255.3%
Net Income	$6M	-$3M	+269.5%